Regulatory
J&J’s Tecvayli Wins EU Nod in a Combination That Slashed Myeloma Progression Risk
The European Commission approved teclistamab plus daratumumab for relapsed multiple myeloma after a trial cut the risk of progression or death by more than 80%.